Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

At Edison, we are on a mission to leverage AI to prevent or cure all diseases. Today, we are announcing a critical step: our first partnership using our AI scientist, Kosmos, to launch new biotech companies. Many of the most transformative new medicines begin life in biotech companies rather...

SGRodriques's profile picture

Sam Rodriques

21,475 subscribers

31,600 görüntüleme • 2 ay önce •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

Enterprise AI adoption will be the hottest topic of 2026. We pre-empted this, and are launching Solaris: a platform to help enterprises understand what’s possible with AI and actually make it happen. We are already live with fast growing companies like Lendi Group, Eucalyptus. And are partnered with incredible companies like Manus, Nebius, Julius AI, Lindy etc. In 2026, we are partnering with HP in APAC to power the future of the AI workforce. More below
0:33

Enterprise AI adoption will be the hottest topic of 2026. We pre-empted this, and are launching Solaris: a platform to help enterprises understand what’s possible with AI and actually make it happen. We are already live with fast growing companies like Lendi Group, Eucalyptus. And are partnered with incredible companies like Manus, Nebius, Julius AI, Lindy etc. In 2026, we are partnering with HP in APAC to power the future of the AI workforce. More below

Annie ❤️‍🔥

60,789 görüntüleme • 8 ay önce

AbCellera CEO Carl Hansen on “redefining” what success looks like in Canada: “One of the things Canada can boast of is terrific science” … “but we are still the only G7 country without a major biopharma company”. “It’s not because we haven’t had successes. It’s because every time that a success starts to look like it’s going to work, we sell it.” … “If you keep selling your dollar bills for pennies, you’re going to wake up 20 years later and say ‘hey we’ve got no money left’. And we’ve been doing that again and again”. “In biotech and in other sectors of tech, the reality is you either start a company that is ambitious enough and big enough to scale and be a global champion, or it’s going to get bought. And when it gets bought, it gets bought by companies that are much bigger. And if you don’t have bigger companies, you lose the companies.” “If there’s one thing that everyone could just get their mind around: We need to build big companies. By whatever means. If we have big companies, we are an acquirer of technology. If we don’t, we are a cheap branch-plant for large multinationals in other jurisdictions.”
1:29

AbCellera CEO Carl Hansen on “redefining” what success looks like in Canada: “One of the things Canada can boast of is terrific science” … “but we are still the only G7 country without a major biopharma company”. “It’s not because we haven’t had successes. It’s because every time that a success starts to look like it’s going to work, we sell it.” … “If you keep selling your dollar bills for pennies, you’re going to wake up 20 years later and say ‘hey we’ve got no money left’. And we’ve been doing that again and again”. “In biotech and in other sectors of tech, the reality is you either start a company that is ambitious enough and big enough to scale and be a global champion, or it’s going to get bought. And when it gets bought, it gets bought by companies that are much bigger. And if you don’t have bigger companies, you lose the companies.” “If there’s one thing that everyone could just get their mind around: We need to build big companies. By whatever means. If we have big companies, we are an acquirer of technology. If we don’t, we are a cheap branch-plant for large multinationals in other jurisdictions.”

Jack Prescott

40,346 görüntüleme • 1 ay önce

We are working on: •Better access to funding. •One single, simple set of rules for innovative companies all over our Union. I want a start-up to scale up easily across Europe, as they could in the US. •Faster AI adoption - we will present an Apply AI Strategy next week.
0:35

We are working on: •Better access to funding. •One single, simple set of rules for innovative companies all over our Union. I want a start-up to scale up easily across Europe, as they could in the US. •Faster AI adoption - we will present an Apply AI Strategy next week.

Ursula von der Leyen

33,446 görüntüleme • 11 ay önce

MASSIVE X COVERUP. It wasn't a 'BUG' today for many suspensions, it was INDIAN MASS REPORT GANGS. WE ARE UNDER AN INVASION BY INDIA, and the 80/20 PLAN -- where 80% OF JOBS AT MANY OF OUR LARGEST COMPANIES WILL GO DIRECT TO INDIA -- and the REMAINING 20% in the US will be at companies that are all INDIANS ON VISAS that have LOCKED AMERICANS OUT OF THEIR OWN COMPANIES.
5:37

MASSIVE X COVERUP. It wasn't a 'BUG' today for many suspensions, it was INDIAN MASS REPORT GANGS. WE ARE UNDER AN INVASION BY INDIA, and the 80/20 PLAN -- where 80% OF JOBS AT MANY OF OUR LARGEST COMPANIES WILL GO DIRECT TO INDIA -- and the REMAINING 20% in the US will be at companies that are all INDIANS ON VISAS that have LOCKED AMERICANS OUT OF THEIR OWN COMPANIES.

Neon White Rabbit

392,437 görüntüleme • 5 ay önce

New data just came out: California’s population grew for another year in a row. We are now the 4th largest economy in the world. We have more Fortune 500 companies than ever before. We dominate every space -- from trade to agriculture to AI -- and we continue to grow.
1:45

New data just came out: California’s population grew for another year in a row. We are now the 4th largest economy in the world. We have more Fortune 500 companies than ever before. We dominate every space -- from trade to agriculture to AI -- and we continue to grow.

Gavin Newsom

507,328 görüntüleme • 1 yıl önce

We live in a golden age of biology. So why are people still dying from disease? Because discovery and development move slower than they should. Today, we’re partnering with Incyte to change that. Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. Incyte will be the first company to deploy it across their pipeline. Work that used to take a team of scientists months now happens in weeks. Patients can't wait, and neither can we.
1:21

We live in a golden age of biology. So why are people still dying from disease? Because discovery and development move slower than they should. Today, we’re partnering with Incyte to change that. Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. Incyte will be the first company to deploy it across their pipeline. Work that used to take a team of scientists months now happens in weeks. Patients can't wait, and neither can we.

Sam Rodriques

7,032,773 görüntüleme • 3 ay önce

We are proud to reach a special milestone as 2023 draws to a close: we recently made our 1,000th investment in companies that originated in Antler residencies around the world. 🌍 As we continue to grow, our scale matters for one reason: we are helping more founders bring disruptive companies into existence to make tomorrow better than today. That's why we exist as the world’s day zero investor. Enormous thanks to our entire global community & especially our founders—you are the heart of everything we do. 🌟
1:29

We are proud to reach a special milestone as 2023 draws to a close: we recently made our 1,000th investment in companies that originated in Antler residencies around the world. 🌍 As we continue to grow, our scale matters for one reason: we are helping more founders bring disruptive companies into existence to make tomorrow better than today. That's why we exist as the world’s day zero investor. Enormous thanks to our entire global community & especially our founders—you are the heart of everything we do. 🌟

Antler

10,811 görüntüleme • 2 yıl önce

#WATCH | Sriharikota, Andhra Pradesh: Pawan Kumar Chandan, CEO and Founder of Skyroot Aerospace, says, "Today, we are here at the Spaceport of India, Sriharikota, where we are going to launch India's first private orbital rocket... The first time in India that a private company has developed an orbital rocket and taken it to the launch site and is going to take off soon. And it's a proud moment for India... very few companies in the world have actually launched a rocket to orbit, and very few companies in the world are operating regular orbital rockets. This is a very unique capability which the world needs. And as an Indian company, we are very proud that we are going to launch our first test flight of Vikram-1 soon..."
5:51

#WATCH | Sriharikota, Andhra Pradesh: Pawan Kumar Chandan, CEO and Founder of Skyroot Aerospace, says, "Today, we are here at the Spaceport of India, Sriharikota, where we are going to launch India's first private orbital rocket... The first time in India that a private company has developed an orbital rocket and taken it to the launch site and is going to take off soon. And it's a proud moment for India... very few companies in the world have actually launched a rocket to orbit, and very few companies in the world are operating regular orbital rockets. This is a very unique capability which the world needs. And as an Indian company, we are very proud that we are going to launch our first test flight of Vikram-1 soon..."

ANI

96,863 görüntüleme • 1 ay önce

In partnership with XPRIZE, we're launching the #XB100: the definitive ranking of the top 100 private deep tech companies. From AI and climate to next-gen biotech and robotics, these businesses are propelling humanity forward. See the list ➡️ In our State of Deep Tech report, we share the benchmarks and trends that emerged from our research, and the challenges facing deep tech founders in the coming years. Read the report ➡️ We also spoke with Xanadu, Anthropic, Generate:Biomedicines, , and Commonwealth Fusion Systems on how their companies are commercializing scientific research. Watch the videos ➡️
0:35

In partnership with XPRIZE, we're launching the #XB100: the definitive ranking of the top 100 private deep tech companies. From AI and climate to next-gen biotech and robotics, these businesses are propelling humanity forward. See the list ➡️ In our State of Deep Tech report, we share the benchmarks and trends that emerged from our research, and the challenges facing deep tech founders in the coming years. Read the report ➡️ We also spoke with Xanadu, Anthropic, Generate:Biomedicines, , and Commonwealth Fusion Systems on how their companies are commercializing scientific research. Watch the videos ➡️

Bessemer

56,873 görüntüleme • 3 yıl önce

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:
0:36

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:

Isomorphic Labs

281,210 görüntüleme • 3 ay önce

Today, we’re announcing Kosmos, our newest AI Scientist, available to use now. Users estimate Kosmos does 6 months of work in a single day. One run can read 1,500 papers and write 42,000 lines of code. At least 79% of its findings are reproducible. Kosmos has made 7 discoveries so far, which we are releasing today, in areas ranging from neuroscience to material science and clinical genetics, in collaboration with our academic beta testers. Three of these discoveries reproduced unpublished findings; four are net new, validated contributions to the scientific literature. AI-accelerated science is here. Our core innovation in Kosmos is the use of a structured, continuously-updated world model. As described in our technical report, Kosmos’ world model allows it to process orders of magnitude more information than could fit into the context of even the longest-context language models, allowing it to synthesize more information and pursue coherent goals over longer time horizons than Robin or any of our other prior agents. In this respect, we believe Kosmos is the most compute-intensive language agent released so far in any field, and by far the most capable AI Scientist available today. The use of a persistent world model also enables single Kosmos trajectories to produce highly complex outputs that require multiple significant logical leaps. As with all of our systems, Kosmos is designed with transparency and verifiability in mind: every conclusion in a Kosmos report can be traced through our platform to the specific lines of code or the specific passages in the scientific literature that inspired it, ensuring that Kosmos’ findings are fully auditable at all times. We are also using this opportunity to announce the launch of Edison Scientific, a new commercial spinout of FutureHouse, which will be focused on commercializing our agents and applying them to automate scientific research in drug discovery and beyond. Edison will be taking over management of the FutureHouse platform, where you can access Kosmos alongside our Literature, Molecules, and Precedent agents (previously Crow, Phoenix, and Owl). Edison will continue to offer free tier usage for casual users and academics, while also offering higher rate limits and additional features for users who need them. You can read more about this spinout on our blog, below. A few important notes if you’re going to try Kosmos. Firstly, Kosmos is different from many other AI tools you might have played with, including our other agents. It is more similar to a Deep Research tool than it is to a chatbot: it takes some time to figure out how to prompt it effectively, and we have tried to include guidelines on this to help (see below). It costs $200/run right now (200 credits per run, and $1/credit), with some free tier usage for academics. This is heavily discounted; people who sign up for Founding Subscriptions now can lock in the $1/credit price indefinitely, but the price ultimately will probably be higher. Again, this is less chatbot and more research tool, something you run on high-value targets as needed. Some caveats are also warranted. Firstly, we find that 80% of Kosmos findings are reproducible, which also means 20% are not -- some things it says will be wrong. Also, Kosmos certainly does produce outputs that are the equivalent to several months of human labor, but it also often goes down rabbit holes or chases statistically significant yet scientifically irrelevant findings. We often run Kosmos multiple times on the same objective in order to sample the various research avenues it can take. There are still a bunch of rough edges on the UI and such, which we are working on. Finally, we are aware that the 6 month figure is much greater than estimates by other AI labs, like METR, about the length of tasks that AI Agents can currently perform. You can read discussion about this in our blog post. Huge congratulations to our team that put this together, led by Ludovico Mitchener and Michaela Hinks: Angela Yiu, Benjamin Chang, Sid Narayanan, Edwin Melville-Green, Albert Bou, Arvis Sulovari, Oz Wassie, Jon Laurent. A particular shout out to Michael Skarlinski and his team that rebuilt the platform for this launch, especially Andy Cai Andy Cai, Richard Magness, Remo Storni, Tyler Nadolski Tyler Nadolski, Mayk Caldas Mayk Caldas, Sam Cox Sam Cox and more. This work would not have been possible without significant contributions from academic collaborators Mathieu Bourdenx, Eric Landsness, Dániel Barabási, Nicky Evans, Tonio Buonassisi, Bruna Gomes, Shriya Reddy, Martha Foiani, and Randall Bateman. We also want to thank our numerous supporters, especially Eric Schmidt, who has been a tremendous ally. We will have more to say about our supporters soon!
0:44

Today, we’re announcing Kosmos, our newest AI Scientist, available to use now. Users estimate Kosmos does 6 months of work in a single day. One run can read 1,500 papers and write 42,000 lines of code. At least 79% of its findings are reproducible. Kosmos has made 7 discoveries so far, which we are releasing today, in areas ranging from neuroscience to material science and clinical genetics, in collaboration with our academic beta testers. Three of these discoveries reproduced unpublished findings; four are net new, validated contributions to the scientific literature. AI-accelerated science is here. Our core innovation in Kosmos is the use of a structured, continuously-updated world model. As described in our technical report, Kosmos’ world model allows it to process orders of magnitude more information than could fit into the context of even the longest-context language models, allowing it to synthesize more information and pursue coherent goals over longer time horizons than Robin or any of our other prior agents. In this respect, we believe Kosmos is the most compute-intensive language agent released so far in any field, and by far the most capable AI Scientist available today. The use of a persistent world model also enables single Kosmos trajectories to produce highly complex outputs that require multiple significant logical leaps. As with all of our systems, Kosmos is designed with transparency and verifiability in mind: every conclusion in a Kosmos report can be traced through our platform to the specific lines of code or the specific passages in the scientific literature that inspired it, ensuring that Kosmos’ findings are fully auditable at all times. We are also using this opportunity to announce the launch of Edison Scientific, a new commercial spinout of FutureHouse, which will be focused on commercializing our agents and applying them to automate scientific research in drug discovery and beyond. Edison will be taking over management of the FutureHouse platform, where you can access Kosmos alongside our Literature, Molecules, and Precedent agents (previously Crow, Phoenix, and Owl). Edison will continue to offer free tier usage for casual users and academics, while also offering higher rate limits and additional features for users who need them. You can read more about this spinout on our blog, below. A few important notes if you’re going to try Kosmos. Firstly, Kosmos is different from many other AI tools you might have played with, including our other agents. It is more similar to a Deep Research tool than it is to a chatbot: it takes some time to figure out how to prompt it effectively, and we have tried to include guidelines on this to help (see below). It costs $200/run right now (200 credits per run, and $1/credit), with some free tier usage for academics. This is heavily discounted; people who sign up for Founding Subscriptions now can lock in the $1/credit price indefinitely, but the price ultimately will probably be higher. Again, this is less chatbot and more research tool, something you run on high-value targets as needed. Some caveats are also warranted. Firstly, we find that 80% of Kosmos findings are reproducible, which also means 20% are not -- some things it says will be wrong. Also, Kosmos certainly does produce outputs that are the equivalent to several months of human labor, but it also often goes down rabbit holes or chases statistically significant yet scientifically irrelevant findings. We often run Kosmos multiple times on the same objective in order to sample the various research avenues it can take. There are still a bunch of rough edges on the UI and such, which we are working on. Finally, we are aware that the 6 month figure is much greater than estimates by other AI labs, like METR, about the length of tasks that AI Agents can currently perform. You can read discussion about this in our blog post. Huge congratulations to our team that put this together, led by Ludovico Mitchener and Michaela Hinks: Angela Yiu, Benjamin Chang, Sid Narayanan, Edwin Melville-Green, Albert Bou, Arvis Sulovari, Oz Wassie, Jon Laurent. A particular shout out to Michael Skarlinski and his team that rebuilt the platform for this launch, especially Andy Cai Andy Cai, Richard Magness, Remo Storni, Tyler Nadolski Tyler Nadolski, Mayk Caldas Mayk Caldas, Sam Cox Sam Cox and more. This work would not have been possible without significant contributions from academic collaborators Mathieu Bourdenx, Eric Landsness, Dániel Barabási, Nicky Evans, Tonio Buonassisi, Bruna Gomes, Shriya Reddy, Martha Foiani, and Randall Bateman. We also want to thank our numerous supporters, especially Eric Schmidt, who has been a tremendous ally. We will have more to say about our supporters soon!

Sam Rodriques

732,619 görüntüleme • 10 ay önce

If we want to improve our health, we first need to know what's going on in our bodies. For this week's episode of 'What's Next' I sat down with Renato Circi of Sava to discuss their breakthrough sensor which provides realtime data on our many different molecules & hormones, starting with glucose. We discuss: - why so many glucose-focussed device companies have failed, and what Sava's done differently - how tracking multiple molecules can help us identify and even prevent chronic diseases - what it's really like spinning-out a deep tech company from a University like Imperial College London - how we could make health regulators more pro-innovation If you're interested in the future of preventative health and data-driven medicine, check out the interview below.
0:36

If we want to improve our health, we first need to know what's going on in our bodies. For this week's episode of 'What's Next' I sat down with Renato Circi of Sava to discuss their breakthrough sensor which provides realtime data on our many different molecules & hormones, starting with glucose. We discuss: - why so many glucose-focussed device companies have failed, and what Sava's done differently - how tracking multiple molecules can help us identify and even prevent chronic diseases - what it's really like spinning-out a deep tech company from a University like Imperial College London - how we could make health regulators more pro-innovation If you're interested in the future of preventative health and data-driven medicine, check out the interview below.

James Wise

14,034 görüntüleme • 2 yıl önce

We are in a race against China so we need the best companies to operate at a speed that gets us to the Moon FIRST. SpaceX has the contract to build the HLS which will get U.S. astronauts there on Artemis III. But, competition and innovation are the keys to our dominance in space so NASA is opening up HLS production to Blue Origin and other great American companies. 🚀
0:53

We are in a race against China so we need the best companies to operate at a speed that gets us to the Moon FIRST. SpaceX has the contract to build the HLS which will get U.S. astronauts there on Artemis III. But, competition and innovation are the keys to our dominance in space so NASA is opening up HLS production to Blue Origin and other great American companies. 🚀

NASA Acting Administrator Sean Duffy

2,680,799 görüntüleme • 10 ay önce

$PLTR Palantir CEO Alex Karp on the AI landscape: “America is in the very beginning of a revolution that we own, the AI revolution. We own it. It should be called the US AI revolution. Every single relevant company in the world is in this country. The second tier of those companies are in this country. The JV team of those companies are in this country. There is no other place at scale to do technology other than America.”
2:01

$PLTR Palantir CEO Alex Karp on the AI landscape: “America is in the very beginning of a revolution that we own, the AI revolution. We own it. It should be called the US AI revolution. Every single relevant company in the world is in this country. The second tier of those companies are in this country. The JV team of those companies are in this country. There is no other place at scale to do technology other than America.”

amit

316,744 görüntüleme • 1 yıl önce

👌🏻🔔🙏🏻🤩 This is a brief update from the USA regarding the exciting developments at Kokoon over the past 10 days. Kokoon is incredibly fortunate to have an American holding company Kokoon Global Inc to oversee and launch operations on an unprecedented scale. After years of meticulous planning, we have finalized all details, and our team of architects and engineers is set to complete the project within the next 3 months. This will allow us to unveil a truly remarkable finished project. The timing for Kokoon’s expansion in the USA could not be more perfect. We are currently developing a state-of-the-art sub-clinic in Beverly Hills and a flagship facility in Miami. These two initiatives alone will revolutionize the medical world. With new leadership driving the U.S.A, the enthusiasm from companies, investors, and partners is extraordinary. Their focus, optimism, and commitment to investing heavily in Kokoon’s healthcare vision are inspiring. We are now poised to take the next step by pursuing a direct listing in the USA, supported by top American legal counsel. I’m joined by Clive from the UK (Kokoon’s lead lawyer). Together, we will travel to secure partner agreements, property deals, and other critical arrangements, ensuring everything aligns with our vision. The Weaver initiative—whether symbolizing our innovative approach or a specific leadership effort—underscores our commitment to weaving transformative solutions into healthcare. For the first time in our history, we control the entire timeline. To everyone following Kokoon’s progress, stay tuned for more updates in the coming days, as we have many positive developments to share. Everything is moving in the right direction.
2:53

👌🏻🔔🙏🏻🤩 This is a brief update from the USA regarding the exciting developments at Kokoon over the past 10 days. Kokoon is incredibly fortunate to have an American holding company Kokoon Global Inc to oversee and launch operations on an unprecedented scale. After years of meticulous planning, we have finalized all details, and our team of architects and engineers is set to complete the project within the next 3 months. This will allow us to unveil a truly remarkable finished project. The timing for Kokoon’s expansion in the USA could not be more perfect. We are currently developing a state-of-the-art sub-clinic in Beverly Hills and a flagship facility in Miami. These two initiatives alone will revolutionize the medical world. With new leadership driving the U.S.A, the enthusiasm from companies, investors, and partners is extraordinary. Their focus, optimism, and commitment to investing heavily in Kokoon’s healthcare vision are inspiring. We are now poised to take the next step by pursuing a direct listing in the USA, supported by top American legal counsel. I’m joined by Clive from the UK (Kokoon’s lead lawyer). Together, we will travel to secure partner agreements, property deals, and other critical arrangements, ensuring everything aligns with our vision. The Weaver initiative—whether symbolizing our innovative approach or a specific leadership effort—underscores our commitment to weaving transformative solutions into healthcare. For the first time in our history, we control the entire timeline. To everyone following Kokoon’s progress, stay tuned for more updates in the coming days, as we have many positive developments to share. Everything is moving in the right direction.

Per Jacob Solli

15,218 görüntüleme • 1 yıl önce

If you are able to donate, we will double it. CNHA is partnering with Alakaʻina Foundation Family of Companies and Kākoʻo Haleakalā to match up to $100,000 in community donations for ʻohana impacted by the devastating wildfires on Maui.
0:37

If you are able to donate, we will double it. CNHA is partnering with Alakaʻina Foundation Family of Companies and Kākoʻo Haleakalā to match up to $100,000 in community donations for ʻohana impacted by the devastating wildfires on Maui.

Hawaiian Council

22,258 görüntüleme • 3 yıl önce

When Adam’s stock price dropped by 92% he borrowed money to buy back $6 billion in stock. That bet made the company more than $60 billion: “If no one's going to buy our shares why don't we just start buying our own shares? The company at the bottom was worth $3.8 billion. And we were generating over a billion dollars of EBITDA. Well in theory we could buy back 20% of the shares of the company just in the next year if we really believed in the path we were on. So we kicked that off. But we did it a little bit differently than what most companies do. Most companies go out and say I'm going to buy shares from the public markets and just take shares back. But you don't know who's on the other side of that trade. On the other hand we knew that we had a cap table where about 50% of the shares were going to sell at some point over the coming years. We had private equity investors that owned roughly 50% of the shares of the company alongside some other founders that were no longer there. So instead of going to the public we went to the shareholders that we knew were going to sell and got them to agree to sell back to us over time. And so for the following 18 months we ended up deploying around $6 billion of buybacks using our own capital and we leveraged some to buy back shares in the company. And over time that ended up creating somewhere in the neighborhood of $50 to $60 billion of actual proceeds from the buyback. It was one of the most successful buybacks in the history of companies.”
1:58

When Adam’s stock price dropped by 92% he borrowed money to buy back $6 billion in stock. That bet made the company more than $60 billion: “If no one's going to buy our shares why don't we just start buying our own shares? The company at the bottom was worth $3.8 billion. And we were generating over a billion dollars of EBITDA. Well in theory we could buy back 20% of the shares of the company just in the next year if we really believed in the path we were on. So we kicked that off. But we did it a little bit differently than what most companies do. Most companies go out and say I'm going to buy shares from the public markets and just take shares back. But you don't know who's on the other side of that trade. On the other hand we knew that we had a cap table where about 50% of the shares were going to sell at some point over the coming years. We had private equity investors that owned roughly 50% of the shares of the company alongside some other founders that were no longer there. So instead of going to the public we went to the shareholders that we knew were going to sell and got them to agree to sell back to us over time. And so for the following 18 months we ended up deploying around $6 billion of buybacks using our own capital and we leveraged some to buy back shares in the company. And over time that ended up creating somewhere in the neighborhood of $50 to $60 billion of actual proceeds from the buyback. It was one of the most successful buybacks in the history of companies.”

David Senra

518,747 görüntüleme • 4 ay önce